Ralinepag - Arena Pharmaceuticals

Drug Profile

Ralinepag - Arena Pharmaceuticals

Alternative Names: APD-811

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Acetic acids; Antihypertensives; Carbamates; Chlorobenzenes; Small molecules
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 05 Dec 2017 Ralinepag licensed to Everest Medicines in China, Taiwan, Hong Kong, Macau, and South Korea
  • 10 Jul 2017 Arena Pharmaceuticals plans a phase III trial for Pulmonary arterial hypertension (PO)
  • 10 Jul 2017 Top-line efficacy and adverse events data from a phase II trial in Pulmonary arterial hypertension released by Arena Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top